Back to search

Peptide record

TPDB06367

BP100 Antibacterial Anticancer Antifungal Cell-penetrating Peptides Hemolysis Toxicity standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06367
BP100
Antibacterial Anticancer Antifungal Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifp Antifungipept CAFPdb CellPPD-MOD CPPsite3.0 PerseuCPP APD_complete HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 11-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KKLFKKILKYL
Physicochemical Analysis
C72H124N16O13
ARNDCEQGHMPSTWV
K
1421.88
10.77
5
0
6
+5
0.89
-0.191
141.82
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
1490
104.79
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
3
L
5
K
0
M
1
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 3 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
11
C72H124N16O13
1421.88
10.77
+5
0.89
-0.191
Free
L
Cationic
Linear
Free
N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O
Evidence Records 55 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2.5-5.0 µM

Target

E. amylovora

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Highly active against E. amylovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.
Evidence 2 Activity

Activity

MIC
Antibacterial
5.0-7.5 µM

Target

v. vesicatoria

Source & Reference

dbAMP DRAMP

Other

Highly active against E. amylovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.0 uM). This peptide appears to have cell penetra
Evidence 3 Activity

Activity

MIC
Antibacterial
2.5-5.0 µM

Target

v. syringae

Source & Reference

dbAMP DRAMP

Other

lovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.0 uM). This peptide appears to have cell penetrating property ( Eggenberger et al., 2011 ).
Evidence 4 Activity

Activity

MIC
Antifungal
2.5-5.0 µM

Target

E. amylovora

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Highly active against E. amylovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.
Evidence 5 Activity

Activity

MIC
Antifungal
5.0-7.5 µM

Target

v. vesicatoria

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Highly active against E. amylovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.0 uM). This peptide appears to have cell penetra
Evidence 6 Activity

Activity

MIC
Antifungal
2.5-5.0 µM

Target

v. syringae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

lovora (MIC 2.5-5.0 uM), X. axonopodis pv. vesicatoria (MIC 5.0-7.5 uM), and P. syringae pv. syringae (MIC 2.5-5.0 uM). This peptide appears to have cell penetrating property ( Eggenberger et al., 2011 ).
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

BY-2 Cells, A. thaliana Cotyledons, And O. Sativa Calli

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
Cytosol
The efficiency of dTat-Sar-EED4 was up to ∼20-fold higher than dTat , R9 and BP101
In vitro
CGGGGGSTTTC
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Target

A. Thaliana Leaves ,N. Benthamiana Leaf And Tomato (Solanum Lycopersicum (S. Lycopersicum) And Solanum Tuberosum)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Synthetic
Cyanine‐3 (Cy3) labeled pDNA (pPpsbA::Rluc)
Cytoplasm and Chloroplasts
In vitro
CCSCSCCSCSTTHHHHSCC
Evidence 9 Activity

Activity

83±6% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
83±6% Hemolysis | 250 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 10 Activity

Activity

95±13% Hemolysis
Toxicity
375 µM
Hemolytic Cytotoxic
95±13% Hemolysis | 375 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 11 Activity

Activity

93±0.8% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
93±0.8% Hemolysis | 250 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 12 Activity

Activity

96±1% Hemolysis
Toxicity
375 µM
Hemolytic Cytotoxic
96±1% Hemolysis | 375 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 13 Activity

Activity

100±0.9% Hemolysis
Toxicity
250-375 µM
Hemolytic Cytotoxic
100±0.9% Hemolysis | 250-375 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 14 Activity

Activity

IC50
Toxicity
57.7±5.8 µM
Cytotoxic
IC50 | 57.7±5.8 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 15 Activity

Activity

IC50
Toxicity
50.6±4.6 µM
Cytotoxic
IC50 | 50.6±4.6 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 16 Activity

Activity

10% Hemolysis
Toxicity
160 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 160 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 17 Activity

Activity

15% Hemolysis
Toxicity
240 µM
Hemolytic Cytotoxic
15% Hemolysis | 240 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 18 Activity

Activity

IC50
Toxicity
53.7±6.3 µM
Cytotoxic
IC50 | 53.7±6.3 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 19 Activity

Activity

IC50
Toxicity
56.3±5.3 µM
Cytotoxic
IC50 | 56.3±5.3 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 20 Activity

Activity

8% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
8% Hemolysis | 160 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 21 Activity

Activity

12% Hemolysis
Toxicity
240 µM
Hemolytic Cytotoxic
12% Hemolysis | 240 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 22 Activity

Activity

IC50
Toxicity
64.4±3.9 µg/mL
Cytotoxic
IC50 | 64.4±3.9 | µg/mL | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 23 Activity

Activity

IC50
Toxicity
56.2±7.3 µM
Cytotoxic
IC50 | 56.2±7.3 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 24 Activity

Activity

15% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
15% Hemolysis | 160 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 25 Activity

Activity

22% Hemolysis
Toxicity
240 µM
Hemolytic Cytotoxic
22% Hemolysis | 240 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 26 Activity

Activity

IC50
Toxicity
51.8±7.2 µM
Cytotoxic
IC50 | 51.8±7.2 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 27 Activity

Activity

IC50
Toxicity
46.2±6.3 µM
Cytotoxic
IC50 | 46.2±6.3 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 28 Activity

Activity

25% Hemolysis
Toxicity
240 µM
Hemolytic Cytotoxic
25% Hemolysis | 240 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 29 Activity

Activity

IC50
Toxicity
40.4±5.2 µM
Cytotoxic
IC50 | 40.4±5.2 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 30 Activity

Activity

IC50
Toxicity
41.3±4.6 µM
Cytotoxic
IC50 | 41.3±4.6 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 31 Activity

Activity

18% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
18% Hemolysis | 160 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 32 Activity

Activity

27% Hemolysis
Toxicity
240 µM
Hemolytic Cytotoxic
27% Hemolysis | 240 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 33 Activity

Activity

54% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
54% Hemolysis | 250 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Improvement of the efficacy of linear undecapeptides against plant-pathogenic bacteria by incorporation of D-amino acids | Appl Environ Microbiol | 2011
Evidence 34 Activity

Activity

50% Hemolysis
Toxicity
>100 µM
Hemolytic Cytotoxic
50% Hemolysis | >100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. | Biochim Biophys Acta | 2013
Evidence 35 Activity

Activity

IC50
Toxicity
57.9±5.2 µM
Cytotoxic
IC50 | 57.9±5.2 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities. | Amino Acids | 2017
Evidence 36 Activity

Activity

(22±2.8)% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
(22±2.8)% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties. | Org Biomol Chem | 2014
Evidence 37 Activity

Activity

IC50
Toxicity
62.5±6.4 µM
Cytotoxic
IC50 | 62.5±6.4 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties. | Org Biomol Chem | 2014
Evidence 38 Activity

Activity

43±1.4% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
43±1.4% Hemolysis | 250 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 39 Activity

Activity

57±4.6% Hemolysis
Toxicity
375 µM
Hemolytic Cytotoxic
57±4.6% Hemolysis | 375 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens. | PLoS One | 2018
Evidence 40 Activity

Activity

IC50
Toxicity
66.8±5.1 µM
Cytotoxic
IC50 | 66.8±5.1 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis and biological evaluation of novel aliphatic acid-conjugated antimicrobial peptides as potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Amino Acids | 2017
Evidence 41 Activity

Activity

7% Hemolysis
Toxicity
1.25 µM
Hemolytic Cytotoxic
7% Hemolysis | 1.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 42 Activity

Activity

9% Hemolysis
Toxicity
2.5 µM
Hemolytic Cytotoxic
9% Hemolysis | 2.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 43 Activity

Activity

13% Hemolysis
Toxicity
5 µM
Hemolytic Cytotoxic
13% Hemolysis | 5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 44 Activity

Activity

18% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
18% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 45 Activity

Activity

36% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
36% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 46 Activity

Activity

59% Hemolysis
Toxicity
40 µM
Hemolytic Cytotoxic
59% Hemolysis | 40 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 47 Activity

Activity

80% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
80% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 48 Activity

Activity

92% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
92% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Alanine scan and (2)H NMR analysis of the membrane-active peptide BP100 point to a distinct carpet mechanism of action. | Biochim Biophys Acta | 2016
Evidence 49 Activity

Activity

79% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
79% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A library of linear undecapeptides with bactericidal activity against phytopathogenic bacteria. | Peptides | 2007
Evidence 50 Activity

Activity

83% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
83% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A library of linear undecapeptides with bactericidal activity against phytopathogenic bacteria. | Peptides | 2007
Evidence 51 Activity

Activity

0% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
0% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Derivatives of the antimicrobial peptide BP100 for expression in plant systems. | PLoS One | 2013
Evidence 52 Activity

Activity

8% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
8% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Derivatives of the antimicrobial peptide BP100 for expression in plant systems. | PLoS One | 2013
Evidence 53 Activity

Activity

18% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
18% Hemolysis | 250 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Derivatives of the antimicrobial peptide BP100 for expression in plant systems. | PLoS One | 2013
Evidence 54 Activity

Activity

% Hemolysis
Toxicity
10 %
Hemolytic
Hemolytic_activity: [Ref.29750913] 10% hemolysis at 64µM against human red blood cell

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochim Biophys Acta. 2018 Aug 1860(8):1502-1516.
Evidence 55 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.
Additional Detail Fields 1 fields
CGGGGGSTTTC CCSCSCCSCSTTHHHHSCC